MetaVia (NASDAQ:MTVA – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08), FiscalAI reports.
MetaVia Stock Up 2.8%
MTVA stock traded up $0.04 during trading hours on Friday, hitting $1.49. The company’s stock had a trading volume of 107,022 shares, compared to its average volume of 549,292. The stock has a 50 day moving average price of $1.72 and a two-hundred day moving average price of $1.75. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The company has a market capitalization of $7.69 million, a PE ratio of -0.29 and a beta of 0.95.
Analyst Ratings Changes
Several research analysts have weighed in on MTVA shares. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research note on Friday, July 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $20.00.
Institutional Investors Weigh In On MetaVia
An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors own 1.37% of the company’s stock.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
